Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

Carrillo-Muñoz, Alfonso-Javier; Quindós, Guillermo; Ruesga, María Teresa; Alonso, R; Valle, Oscar del; Hernández-Molina, Juan Manuel; McNicholas, Paul M.; Loebenberg, David; Santos, Patricia

doi:10.1093/jac/dki022

Cited by 29 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These concentrations, which are sub-inhibitory for yeasts, were previously determined in the isolated strains in our laboratory, and proved to coincide with the ones employed in our previous work and in other authors' work (16,19,20). Minimum inhibitory concentration (MIC) was determined using the agar dilution method, which defines MIC as the lowest antifungal drug concentration where a considerable decrease in the colony size is observed compared to control growth.…”

Section: Antifungal Agentssupporting

confidence: 79%

Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans

Se¹,

Ma²,

Barembaum³

et al. 2011

Med Oral

View full text Add to dashboard Cite

Objective: The aim of this work was to assess the antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on virulence factors of Candida albicans. Study Design: Ten isolated strains of Candida albicans obtained from 10 patients with oral candidiasis and a collection strain of C. albicans were treated with antifungal agents in different concentrations or combinations of them. Virulence factors analyzed were the cell surface hydrophobicity, the germinative tube development, the phospholipase activity and the post-antifungal effect of that exposure. Results: Virulence factors of the isolated strains obtained from patients together with the collection strain showed significant decreases with the different antifungal treatments, except for hydrophobicity and phospholipase activity. The development of germinative tube was the most sensitive factor to all the antifungal agents used. Untreated strains as well as the ones treated with antifungal agents showed a positive correlation among the virulence factors analyzed. No synergic effects arose from the combinations of the used drugs. Conclusions: C. albicans isolated strains from patients showed high phospholipase activity and germinative tube production, which corroborates their capacity to infect the oral mucosa and the high prevalence of species. As a whole, our results imply that short exposures to sub-inhibitory concentrations of the antifungal agents under analysis, isolated or combined, can modulate the way virulence factors get manifested, thus decreasing their pathogenicity.

show abstract

Section: Antifungal Agentssupporting

confidence: 79%

Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans

Se¹,

Ma²,

Barembaum³

et al. 2011

Med Oral

View full text Add to dashboard Cite

show abstract

“…Examples of new azole antifungals being evaluated for clinical development or in clinical testing include ravuconazole (69) [89], CS-758 [90] (70), and posaconazole (71) [91].…”

Section: Additional Azoles In Developmentmentioning

confidence: 99%

Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules

Kirk

2006

Journal of Fluorine Chemistry

842

264

View full text Add to dashboard Cite

“…It is active against opportunistic, endemic, and dermatophytic fungi (10, 13, 14, 15) as well as Candida, Cryptococcus, and other yeast species (1,3,17,22,23), including isolates that exhibit resistance to fluconazole and itraconazole (3,10,23). It also has a potent activity in vitro against Aspergillus species; posaconazole appears to be more active in vitro against Aspergillus than are amphotericin B, itraconazole, voriconazole, and ravuconazole, inhibiting 95% of isolates at a MIC of Յ1 g/ml (2, 9, 24).…”

mentioning

confidence: 99%

Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi

Cuenca‐Estrella

Gómez-López

Mellado

et al. 2006

Antimicrob Agents Chemother

269

173

View full text Add to dashboard Cite

We have compared the activities of posaconazole and other currently available antifungal agents against a collection of 3,378 clinical isolates of yeasts and filamentous fungi. A total of 1,997 clinical isolates of Candida spp., 359 of other yeast species, 697 strains of Aspergillus spp., and 325 nondermatophyte non-Aspergillus spp. were included. The average geometric means of the MICs of agents that were tested against Candida spp. were 0.23 g/ml for amphotericin B, 0.29 g/ml for flucytosine, 0.97 g/ml for fluconazole, 0.07 g/ml for itraconazole, 0.04 g/ml for voriconazole, 0.15 g/ml for caspofungin, and 0.03 g/ml for posaconazole. Voriconazole and posaconazole were active in vitro against the majority of isolates, with resistance to fluconazole and itraconazole, and against Cryptococcus neoformans and other Basidiomycota yeasts. Posaconazole was the most active of antifungal agents tested against Aspergillus spp., with an average geometric mean of 0.10 g/ml. It was active against Paecilomyces spp., Penicillium spp., Scedosporium apiospermum, and some black fungi, such as Alternaria spp. Multiresistant filamentous fungi, such as Scedosporium prolificans, Scopulariopsis brevicaulis, and Fusarium solani, were also resistant to voriconazole, caspofungin, and posaconazole. Amphotericin B and posaconazole were found to be active against most of the Mucorales strains tested. Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species.Posaconazole is a new triazole agent with an extended spectrum of in vitro activity. It is active against opportunistic, endemic, and dermatophytic fungi (10, 13, 14, 15) as well as Candida, Cryptococcus, and other yeast species (1,3,17,22,23), including isolates that exhibit resistance to fluconazole and itraconazole (3,10,23). It also has a potent activity in vitro against Aspergillus species; posaconazole appears to be more active in vitro against Aspergillus than are amphotericin B, itraconazole, voriconazole, and ravuconazole, inhibiting 95% of isolates at a MIC of Յ1 g/ml (2, 9, 24). In addition, the new triazoles have been shown to have antifungal activity against other species of filamentous fungi, such as Penicillium spp., Paecilomyces spp., and Acremonium spp., and Sporothrix schenckii as well as some isolates of Fusarium spp., Scedosporium apiospermum, and black fungi (9,10,13,18,24,30). Most notably, posaconazole is more active than the other triazole compounds against zygomycetes, with MICs around or below 1 g/ml. Within the class of Zygomycetes, posaconazole appears to be more active against Rhizopus spp. and Absidia corymbifera than against Mucor spp., which is consistent with the prior observation that the zygomycetes appear to be a heterogeneous group with regard to their susceptibilities to antifungal agents (7,9, 16,24,29).We have analyzed the in vitro activity of posaconazole and other currently available antifungal agents against a collection of 3,378 clinical isolates of yeasts and fila...

show abstract

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

Abstract: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.

Cited by 29 publications

References 25 publications

Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans

Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans

Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules

Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi

Contact Info

Product

Resources

About